<DOC>
	<DOCNO>NCT02808975</DOCNO>
	<brief_summary>The objective study assess safety efficacy adalimumab prior surgery subject moderate severe Hidradenitis Suppurativa ( HS ) surgical candidate .</brief_summary>
	<brief_title>Safety Efficacy Humira ( Adalimumab ) Hidradenitis Suppurativa ( HS ) Peri-Surgically ( SHARPS Study )</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participant must skin lesion diagnostic Hidradenitis Suppurativa ( HS ) least 1 year ( 365 day ) prior Baseline visit Participant must least 3 distinct anatomical region involve inflammatory ( also term 'active ' ) HS lesion ; plus either one axilla one inguinal region ( limited inguinocrural fold adjacent area ) require excisional surgery , least one affected HS region ( e.g. , contralateral inguinal region , buttock , inframammary region ) rat Hurley Stage II III Participant must total abscess inflammatory nodule ( AN ) count great equal 3 Baseline visit within HS nonsurgical sit The HS surgical site must contain least one active HS lesion The HS surgical site must require excisional surgery large enough require heal secondary intention assess designate surgeon Has draining fistula count great 20 Baseline visit Requires surgery anatomical site unilateral axilla inguinal region site Requires surgical management prior Week 13 Requires , base designate surgeon 's assessment , excisional surgery primary closure method closure beneficial participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>secondary intention</keyword>
	<keyword>Hidradenitis Suppurativa</keyword>
	<keyword>Hurley Stage I , II , III</keyword>
	<keyword>adalimumab</keyword>
	<keyword>axilla</keyword>
	<keyword>abcess inflammatory nodule ( AN ) count</keyword>
	<keyword>inguinal region</keyword>
</DOC>